Mahdi Ghatrehsamani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Mahdi Ghatrehsamani has a total of 77 co-authors. Here are the top co-authors by number of shared publications:
Amin Soltani
Cellular and Molecular Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran
8 shared publications- Fatemeh Elahian
Cellular and Molecular Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran
3 shared publications Hedayatollah Shirzad
Cellular and Molecular Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran
3 shared publications- Seyed Abbas Mirzaei
Department of Medical Biotechnology, School of Advanced Technologies, Shahrekord University of Medical Sciences, Shahrekord, Iran
3 shared publications - Atarodalsadat Mostafavinia
Department of Anatomical Sciences & Cognitive Neuroscience, Faculty of Medicine, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran
2 shared publications - Hajar Yaghoobi
Clinical Biochemistry Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran
2 shared publications
Latest Publications
- Open Access
- 5 May 2026
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 24 (1)
A novel combination for in vivo breast cancer treatment: TAK1 inhibition combined with metformin and Lentinula edodes compounds synergistically reinvigorates CD8+ T Cells
Breast cancer (BC) is the most prevalent cancer among women, and retrieving the anti-tumor function of the immune system seems a promising treatment approa
- 5 May 2026
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 24 (1)
Open AccessA novel combination for in vivo breast cancer treatment: TAK1 inhibition combined with metformin and Lentinula edodes compounds synergistically reinvigorates CD8+ T Cells
Breast cancer (BC) is the most prevalent cancer among women, and retrieving the anti-tumor function of the immune system seems a promising treatment approa
- 28 October 2025
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 198 (Pt B) , 111258
Design and development of anticancer peptide-conjugated daunorubicin: Smart targeting systems for multidrug resistance gastric cancer cells
- 28 October 2025
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 198 (Pt B) , 111258
Design and development of anticancer peptide-conjugated daunorubicin: Smart targeting systems for multidrug resistance gastric cancer cells
- 10 August 2024
- Published by Springer Nature in Cytotechnology
- Vol. 76 (6) , 761-775
Conditioned media from human adipose tissue-derived mesenchymal stem cells: potential effect on peripheral blood mononuclear cells in co-culture with HeLa cell line
The use of mesenchymal stem cells (MSCs) for the treatment of various diseases is being investigated, however, their use in cervical cancer has not been well-studied. Here, we examined the impact of collected MSC–conditioned medium (CM) on 1 to 5 days on apoptosis, proliferation, and cytokine production of peripheral blood mononuclear cells (PBMCs) when co-cultured alongside the HeLa cell line for 24, 48, and 72 h by CFSE assay, flow cytometry, and real-time PCR, respectively. We found that CMs collected on the third day of MSCs culture significantly increased the proliferation of PBMCs and decreased the proliferation of HeLa cells after 48 h. CMs showed no significant effects on cell death, whereas it significantly increased the apoptosis of HeLa cells. Real-time PCR analysis showed that the presence of CM collected on the third day of MSCs culture caused a significant increase in the gene expression of IL2, IFN-γ, and TGF-β in PBMCs after 48 h co-culture with HeLa cells. The data mentioned earlier demonstrate that MSC–CM can induce the growth and endurance of PBMCs while concurrently culturing HeLa cells. This observation indicates their promising potential as immunomodulatory therapies for cervical cancer cells. Nevertheless, additional investigation is imperative to comprehensively comprehend the fundamental mechanisms and refine therapeutic strategies involving PBMCs and mesenchymal stem cells.
- 10 August 2024
- Published by Springer Nature in Cytotechnology
- Vol. 76 (6) , 761-775
Conditioned media from human adipose tissue-derived mesenchymal stem cells: potential effect on peripheral blood mononuclear cells in co-culture with HeLa cell line
The use of mesenchymal stem cells (MSCs) for the treatment of various diseases is being investigated, however, their use in cervical cancer has not been well-studied. Here, we examined the impact of collected MSC–conditioned medium (CM) on 1 to 5 days on apoptosis, proliferation, and cytokine production of peripheral blood mononuclear cells (PBMCs) when co-cultured alongside the HeLa cell line for 24, 48, and 72 h by CFSE assay, flow cytometry, and real-time PCR, respectively. We found that CMs collected on the third day of MSCs culture significantly increased the proliferation of PBMCs and decreased the proliferation of HeLa cells after 48 h. CMs showed no significant effects on cell death, whereas it significantly increased the apoptosis of HeLa cells. Real-time PCR analysis showed that the presence of CM collected on the third day of MSCs culture caused a significant increase in the gene expression of IL2, IFN-γ, and TGF-β in PBMCs after 48 h co-culture with HeLa cells. The data mentioned earlier demonstrate that MSC–CM can induce the growth and endurance of PBMCs while concurrently culturing HeLa cells. This observation indicates their promising potential as immunomodulatory therapies for cervical cancer cells. Nevertheless, additional investigation is imperative to comprehensively comprehend the fundamental mechanisms and refine therapeutic strategies involving PBMCs and mesenchymal stem cells.
- 15 April 2024
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 267, 131517
In silico design of a novel multi-epitope vaccine against HCV infection through immunoinformatics approaches
- 15 April 2024
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 267, 131517
In silico design of a novel multi-epitope vaccine against HCV infection through immunoinformatics approaches
- 15 February 2024
- Published by Taylor & Francis in Epigenomics
- Vol. 16 (5) , 277-292
Epigenetic Disruption of Histone Deacetylase-2 Accelerated Apoptotic Signaling and Retarded Malignancy in Gastric Cells
Background: The objective of this research was to determine whether HDAC2 function is associated with gastric cancer progression. Methods: HDAC2 was knocked out in EPG85.257 cells using CRISPR/Cas9... Plain language summary DNA changes are the main causes of cancer. Therefore, finding easy ways to manipulate and correct DNA changes has been the biggest medical concern in cancer treatment. Resear... Tweetable abstract Epigenetic disruption of histone deacetylase-2 improved gastric cancer chemotherapy and apoptosis signaling, and induced S-phase cell cycle arrest.
- 15 February 2024
- Published by Taylor & Francis in Epigenomics
- Vol. 16 (5) , 277-292
Epigenetic Disruption of Histone Deacetylase-2 Accelerated Apoptotic Signaling and Retarded Malignancy in Gastric Cells
Background: The objective of this research was to determine whether HDAC2 function is associated with gastric cancer progression. Methods: HDAC2 was knocked out in EPG85.257 cells using CRISPR/Cas9... Plain language summary DNA changes are the main causes of cancer. Therefore, finding easy ways to manipulate and correct DNA changes has been the biggest medical concern in cancer treatment. Resear... Tweetable abstract Epigenetic disruption of histone deacetylase-2 improved gastric cancer chemotherapy and apoptosis signaling, and induced S-phase cell cycle arrest.
- 17 August 2023
- Published by Springer Nature in Molecular Biology Reports
- Vol. 50 (10) , 8319-8328
Effects of bromodomain and extra-terminal inhibitor JQ1 and interleukin-6 on breast cancer cells
Background Bromodomain and extra-terminal (BET) proteins are recognized acetylated lysine of histone 4 and act as scaffolds to recruit many other proteins to promoters and enhancers of active genes, especially at the super-enhancers of key genes, driving the transcription process and have been identified as potential therapeutic targets in breast cancer. However, the efficacy of BET inhibitors such as JQ1 in breast cancer therapy is impeded by interleukin-6 (IL-6) through an as-yet-defined mechanism. Methods and results We investigated the interplay between IL-6 and JQ1 in MCF-7 and MDA-MB-231 human breast cancer cells. The results demonstrate that the efficacy of JQ1 on the inhibition of cell growth and apoptosis was stronger in MDA-MB-231 cells than in MCF-7 cells. Further, MCF-7 cells, but not MDA-MB-231 cells, exhibited increased expression of CXCR4 following IL-6 treatment. JQ1 significantly reduced CXCR4 surface expression in both cell lines and diminished the effects of IL-6 pre-treatment on MCF-7 cells. While IL-6 suppressed the extension of breast cancer stem cells in MCF-7 cells, JQ1 impeded its inhibitory effect. In MCF-7 cells JQ1 increased the number of senescent cells in a time-dependent manner. Conclusion Analysis of gene expression indicated that JQ1 and IL-6 synergistically increase SNAIL expression and decrease c-MYC expression in MCF-7 cells. So, the BET proteins are promising, novel therapeutic targets in late-stage breast cancers. BET inhibitors similar to JQ1 show promise as therapeutic candidates for breast cancers, especially when triple-negative breast cancer cells are increased and/or tumor-promoting factors like IL-6 exist in the tumor microenvironment.
- 17 August 2023
- Published by Springer Nature in Molecular Biology Reports
- Vol. 50 (10) , 8319-8328
Effects of bromodomain and extra-terminal inhibitor JQ1 and interleukin-6 on breast cancer cells
Background Bromodomain and extra-terminal (BET) proteins are recognized acetylated lysine of histone 4 and act as scaffolds to recruit many other proteins to promoters and enhancers of active genes, especially at the super-enhancers of key genes, driving the transcription process and have been identified as potential therapeutic targets in breast cancer. However, the efficacy of BET inhibitors such as JQ1 in breast cancer therapy is impeded by interleukin-6 (IL-6) through an as-yet-defined mechanism. Methods and results We investigated the interplay between IL-6 and JQ1 in MCF-7 and MDA-MB-231 human breast cancer cells. The results demonstrate that the efficacy of JQ1 on the inhibition of cell growth and apoptosis was stronger in MDA-MB-231 cells than in MCF-7 cells. Further, MCF-7 cells, but not MDA-MB-231 cells, exhibited increased expression of CXCR4 following IL-6 treatment. JQ1 significantly reduced CXCR4 surface expression in both cell lines and diminished the effects of IL-6 pre-treatment on MCF-7 cells. While IL-6 suppressed the extension of breast cancer stem cells in MCF-7 cells, JQ1 impeded its inhibitory effect. In MCF-7 cells JQ1 increased the number of senescent cells in a time-dependent manner. Conclusion Analysis of gene expression indicated that JQ1 and IL-6 synergistically increase SNAIL expression and decrease c-MYC expression in MCF-7 cells. So, the BET proteins are promising, novel therapeutic targets in late-stage breast cancers. BET inhibitors similar to JQ1 show promise as therapeutic candidates for breast cancers, especially when triple-negative breast cancer cells are increased and/or tumor-promoting factors like IL-6 exist in the tumor microenvironment.
- 11 November 2022
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 223 (Pt A) , 732-754
CRISPR/Cas9 as precision and high-throughput genetic engineering tools in gastrointestinal cancer research and therapy
- 11 November 2022
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 223 (Pt A) , 732-754
CRISPR/Cas9 as precision and high-throughput genetic engineering tools in gastrointestinal cancer research and therapy
- 3 August 2020
- Published by Taylor & Francis in Biotechnic & Histochemistry
- Vol. 96 (4) , 287-295
The relation between the ghrelin receptor and FOXP3 in bladder cancer
Immune responses play an important role in the fate of bladder cancer tumors. Treg cells are immunosuppressive and down-regulate the proliferation of effector T cells, which favor tumor survival. Ghrelin is a hormone that stimulates release of growth hormone and anti-inflammatory response to cancer cells. Ghrelin also is a gastrointestinal hormone that regulates immune responses via the growth hormone secretagogue receptor (GHS-R1a). The relation among ghrelin, its receptor, and Treg cells that surround bladder tumors is not clear. We found that Foxp3+ T and GHS-R1a cells are increased significantly in bladder tumor tissues. Therefore, we suggest that ghrelin may increase the number of Treg cells in the tumor and suppress activity of the immune system against bladder cancer.
- 3 August 2020
- Published by Taylor & Francis in Biotechnic & Histochemistry
- Vol. 96 (4) , 287-295
The relation between the ghrelin receptor and FOXP3 in bladder cancer
Immune responses play an important role in the fate of bladder cancer tumors. Treg cells are immunosuppressive and down-regulate the proliferation of effector T cells, which favor tumor survival. Ghrelin is a hormone that stimulates release of growth hormone and anti-inflammatory response to cancer cells. Ghrelin also is a gastrointestinal hormone that regulates immune responses via the growth hormone secretagogue receptor (GHS-R1a). The relation among ghrelin, its receptor, and Treg cells that surround bladder tumors is not clear. We found that Foxp3+ T and GHS-R1a cells are increased significantly in bladder tumor tissues. Therefore, we suggest that ghrelin may increase the number of Treg cells in the tumor and suppress activity of the immune system against bladder cancer.